BridgeMD
Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin receptor 2 imaging with [68Ga]Ga-DOTA-TOC PET/CT: the NACASOR trial
EU CTIS ID: 2025-520689-23-00
What this study is testing
To determine feasibility of assessing tumor SSTR2 expression in patients with EBV-associated NPC in a non-endemic region by repeat [68Ga]Ga-DOTA-TOC PET imaging
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Stage IB-IVA NPC (AJCC 9th edition), EBV positive determined by Epstein–Barr virus–encoded RNA (EBER).
- Planned treatment with induction chemotherapy or CRT without induction chemotherapy.
- Age ≥ 18 years.
- Signed informed consent.
- Willingness and ability to comply with all protocol required procedures.
- Negative serum pregnancy test at screening in women of childbearing potential.
You likely can't join if
- Previous treatment with chemotherapy or radiotherapy for NPC.
- Treatment with any investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to [68Ga]Ga-DOTA-TOC injection.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or that may affect the interpretation of the results or render the patient at high risk from complications.
- Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Inability to lie in supine position for 25 minutes.
- Patients who are pregnant or breastfeeding.
See the full eligibility criteria
- Stage IB-IVA NPC (AJCC 9th edition), EBV positive determined by Epstein–Barr virus–encoded RNA (EBER).
- Planned treatment with induction chemotherapy or CRT without induction chemotherapy.
- Age ≥ 18 years.
- Signed informed consent.
- Willingness and ability to comply with all protocol required procedures.
- Negative serum pregnancy test at screening in women of childbearing potential.
- Archival tumor tissue available.
- Previous treatment with chemotherapy or radiotherapy for NPC.
- Treatment with any investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to [68Ga]Ga-DOTA-TOC injection.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or that may affect the interpretation of the results or render the patient at high risk from complications.
- Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Inability to lie in supine position for 25 minutes.
- Patients who are pregnant or breastfeeding.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.